Biohaven Ltd. (NYSE:BHVN – Get Rating) – Cantor Fitzgerald raised their FY2023 EPS estimates for Biohaven in a report issued on Tuesday, May 16th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($4.53) for the year, up from their prior forecast of ($4.92). Cantor Fitzgerald has a “Overweight” rating and a $31.00 price objective on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($5.25) per share.
BHVN has been the topic of several other research reports. SVB Securities began coverage on shares of Biohaven in a research note on Tuesday, January 24th. They set an “outperform” rating and a $24.00 price target on the stock. SVB Leerink reaffirmed an “outperform” rating and set a $24.00 price target on shares of Biohaven in a research note on Tuesday, January 24th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $38.39.
Biohaven Trading Up 1.7 %
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of BHVN. US Bancorp DE boosted its holdings in shares of Biohaven by 19.1% in the 1st quarter. US Bancorp DE now owns 586 shares of the company’s stock valued at $70,000 after buying an additional 94 shares during the period. Cetera Advisor Networks LLC acquired a new position in Biohaven during the 1st quarter valued at about $332,000. AlphaCrest Capital Management LLC acquired a new position in Biohaven during the 1st quarter valued at about $344,000. BlackRock Inc. boosted its stake in Biohaven by 0.5% during the 1st quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock valued at $552,163,000 after purchasing an additional 21,586 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Biohaven by 55.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 82,599 shares of the company’s stock valued at $9,794,000 after purchasing an additional 29,413 shares during the period. 98.01% of the stock is owned by institutional investors and hedge funds.
Biohaven Company Profile
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.
- Get a free copy of the StockNews.com research report on Biohaven (BHVN)
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
- Foot Locker And The Ebbing Tide Of Discretionary Spending
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.